The autoimmune lymphoproliferative syndrome: an experiment of nature involving lymphocyte apoptosis

@article{Fleisher2008TheAL,
  title={The autoimmune lymphoproliferative syndrome: an experiment of nature involving lymphocyte apoptosis},
  author={Thomas A. Fleisher},
  journal={Immunologic Research},
  year={2008},
  volume={40},
  pages={87-92}
}
  • T. Fleisher
  • Published 2008
  • Medicine, Biology
  • Immunologic Research
Autoimmune lymphproliferative syndrome (ALPS) is a human disorder that has been characterized in the past two decades at both a functional and a genetic level. The underlying basis for this disorder is a defect in lymphocyte apoptosis that alters immune homeostasis resulting in an expansion of a normally rare circulating lymphocyte, the alpha beta double negative T cell. The abnormality in Fas mediated apoptosis underlying ALPS serves as a risk factor for autoimmunity involving blood cells and… 

Autoimmune lymphoproliferative syndrome.

  • H. Ören
  • Medicine, Biology
    Turkish journal of haematology : official journal of Turkish Society of Haematology
  • 2006
TLDR
Individuals with ALPS frequently suffer autoimmune complications, primarily hemolytic anemia and thrombocytopenia and they also have an elevated incidence of Hodgkin’s and non-Hodgkins lymphoma.

Autoimmune Lymphoproliferative Syndrome

TLDR
Treatment with the antimalarial drug pyrimethamine/sulfadoxine (25/500mg per tablet) seems to be a new, well tolerated, and efficient approach, although larger studies will have to demonstrate the true value of this drug in patients with ALPS.

Autoimmune Lymphoproliferative Syndrome

TLDR
Serologic testing is critical in the evaluation of individuals with ALPS, which is characterized by massive lymphoadenopathy, splenomegaly, autoimmunity including episodes of immune hemolityc anemia, thrombocytopenia, and neutropenia.

Autoimmune Lymphoproliferative Syndrome

TLDR
The immune system cannot properly regulate the number of immune system cells and accumulation of excess lymphocytes results in enlargement of the lymph nodes, the liver, and the spleen.

Autoimmune Lymphoproliferative Syndrome

  • Dongyou Liu
  • Medicine, Biology
    Handbook of Tumor Syndromes
  • 2020
TLDR
The immune system cannot properly regulate the number of immune system cells and accumulation of excess lymphocytes results in enlargement of the lymph nodes, the liver, and the spleen.

[Autoimmune lymphoproliferative syndrome].

TLDR
Both children are treated with mycophenolate mofetil with good response and ALPS is an underestimated entity that must be considered in non malign lymphoproliferation, autoimmunity and expansion of an unusual population of a/ßCD3+CD4-CD8-(double-negative T cells>1%).

Primary immunodeficiencies (PIDs) presenting with cytopenias.

  • L. Notarangelo
  • Medicine, Biology
    Hematology. American Society of Hematology. Education Program
  • 2009
TLDR
Among autoimmune manifestations in patients with PID, cytopenias are particularly common and occur in 22% to 48% of patients with common variable immunodeficiencies (CVIDs), and are more frequent among CVID patients with splenomegaly and granulomatous disease.

Genetic Predispositions for Hematologic and Lymphoid Disorders

TLDR
The disorders predisposing to hematolymphoids neoplasias addressed in this chapter are presented and an attempt was made to include in this table the processes where there is sufficient documentation of increased risks of developing hematologic or lymphoid neoplasms.

Flow Cytometric Evaluation of Primary Immunodeficiencies.

References

SHOWING 1-10 OF 19 REFERENCES

Autoimmune lymphoproliferative syndrome

TLDR
Defects in multiple molecules within the Fas apoptotic pathway may result in autoimmune lymphoproliferative syndrome and, despite recent advances, a number of patients remain with unidentified genetic defects.

Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity.

TLDR
Fas expression and function were analyzed in three children with a lymphoproliferative syndrome and may provide a molecular basis for some autoimmune diseases in humans.

Autoimmune lymphoproliferative syndrome with somatic Fas mutations.

TLDR
Somatic heterozygous mutations of Fas can cause a sporadic form of ALPS by allowing lymphoid precursors to resist the normal process of cell death.

Pathological findings in human autoimmune lymphoproliferative syndrome.

Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance.

TLDR
The location of mutations within APT1 strongly influences the development and the severity of ALPS, with dominant inhibition of apoptosis much more pronounced in mutants affecting the intracellular, versus extracellular, portion of the Fas receptor.

Clincal, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis.

TLDR
Evidence is provided that apoptosis of activated lymphocytes is an important mechanism for maintaining immunologic homeostasis and self-tolerance in humans and in vitro abnormalities of lymphocyte apoptosis are associated with abnormal lymphoproliferation and autoimmunity.

Autoimmune lymphoproliferative syndromes: genetic defects of apoptosis pathways

TLDR
The absence of lymproliferation in engineered mutants of ‘death pathways’ suggests that additional events are necessary to recapitulate the overt phenotype of ALPS patients or MRL/lpr mice.

Correction of autoimmune lymphoproliferative syndrome by bone marrow transplantation

TLDR
This is the first reported case of ALPS in which BMT was successfully attempted for correction of a Fas deficiency, and the patient underwent BMT from an unrelated donor.

Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity.

TLDR
Patients with the Canale-Smith syndrome have mutations in Fas, which implicates this gene in the accumulation of lymphocytes and the autoimmunity characteristic of the syndrome.